CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models

Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells

(2014) Akemi Kosaka et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Agonistic Anti-CD40 Antibody Therapy is Effective Against Postoperative Cancer Recurrence and Metastasis in a Murine Tumor Model

(2013) Andrea Khong et al.   JOURNAL OF IMMUNOTHERAPY

Dendritic Cell Vaccine for Recurrent High-Grade Gliomas in Pediatric and Adult Subjects

(2013) Ashish H. Shah et al.   NEUROSURGERY

IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas

(2011) Ichiyo Shibahara et al.   International Journal of Clinical Oncology

Sox11 Prevents Tumorigenesis of Glioma-Initiating Cells by Inducing Neuronal Differentiation

(2009) T. Hide et al.   CANCER RESEARCH

Monoclonal antibodies for cancer immunotherapy

(2009) Louis M Weiner et al.   LANCET

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Immune Therapy for Cancer

(2008) Michael Dougan et al.   Annual Review of Immunology